Analyst firms · Citigroup · BIOA
Citigroup BIOA price target and rating history
BioAge Labs Inc. (BIOA) · Health Care
Citigroup rates BioAge Labs Inc. (BIOA) Buy with a $10 price target, as of its latest action on Oct 22, 2025. It has published 3 rating actions on BIOA since October 2024, including 1 upgrade and 1 downgrade. Across 8 firms with a BIOA price target in the last 12 months, the median target is $45.
- Current rating
- Buy
- Price target
- $10
- Median target, all firms
- $45
- Actions on BIOA
- 3
Citigroup price target on BIOA
Every Citigroup rating on BIOA
- Oct 22, 2025
- Dec 9, 2024
- Oct 21, 2024
How other firms rate BIOA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $8 | Oct 12, 2026 |
| Roth Capital | Buy | $36 | May 27, 2026 |
| BTIG | Buy | $40 | May 13, 2026 |
| Needham | Buy | $50 | Mar 27, 2026 |
| Oppenheimer | Outperform | $60 | Feb 25, 2026 |
| Jefferies | Buy | $62 | Feb 18, 2026 |
| Piper Sandler | Overweight | $73 | Jan 27, 2026 |
| Morgan Stanley | Equal-Weight | $12 | Dec 5, 2025 |
Questions about Citigroup and BIOA
- What is Citigroup's price target for BIOA?
- Citigroup's latest stated price target for BioAge Labs Inc. (BIOA) is $10, from its action on Oct 22, 2025.
- What is Citigroup's rating on BIOA?
- Citigroup rates BIOA Buy, a bullish rating, as of Oct 22, 2025.
- When did Citigroup last change its view on BIOA?
- On Oct 22, 2025, Citigroup upgrades to Buy from Neutral, price target $10.
- How does Citigroup's BIOA target compare with other analysts?
- Across 8 firms with a BIOA price target in the last 12 months, the median target is $45.
More BIOA rating histories
All Citigroup ratingsBIOA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.